Fresenius Medical Care (NYSE:FMS) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Fresenius Medical Care (NYSE:FMS) released its quarterly earnings data on Tuesday. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.41 by $0.07, Zacks reports. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%.

Fresenius Medical Care Stock Up 1.1 %

Shares of NYSE:FMS opened at $23.56 on Tuesday. The stock has a market capitalization of $13.83 billion, a P/E ratio of 19.53, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $25.25. The stock’s 50-day moving average price is $23.39 and its 200-day moving average price is $21.74. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Analysts Set New Price Targets

A number of research firms recently weighed in on FMS. Truist Financial lifted their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Berenberg Bank began coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.